Trial Profile
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications Severe fever with thrombocytopenia syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors FUJIFILM Toyama Chemical; Toyama Chemical
- 26 Feb 2018 New trial record